Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Consortium of Investigators of Modifiers of BRCA1/2 |
RCV000258351 | SCV000327765 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 2 | 2015-10-02 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001055989 | SCV001220406 | pathogenic | Hereditary breast ovarian cancer syndrome | 2020-07-30 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This sequence change affects a donor splice site in intron 9 of the BRCA2 gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product. This variant is not present in population databases (ExAC no frequency). This variant has been observed in a family with high risk of breast and/or ovarian cancer (PMID: 29446198). ClinVar contains an entry for this variant (Variation ID: 267687). Experimental studies have shown that disruption of this splice site affects mRNA splicing (PMID: 30883759). Donor and acceptor splice site variants typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in BRCA2 are known to be pathogenic (PMID: 20104584). |
Myriad Genetics, |
RCV000258351 | SCV004932397 | likely pathogenic | Breast-ovarian cancer, familial, susceptibility to, 2 | 2024-02-06 | criteria provided, single submitter | clinical testing | This variant is considered likely pathogenic. This variant occurs within a consensus splice junction and is predicted to result in abnormal mRNA splicing of either an out-of-frame exon or an in-frame exon necessary for protein stability and/or normal function. |
Laboratory for Genotyping Development, |
RCV003165716 | SCV002758120 | pathogenic | Gastric cancer | 2021-07-01 | no assertion criteria provided | research |